Search
for
Sort by
Research 601–630 of 774
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
- The influence of interferon on healthy and diseased skin
- Alopecia Areata: An Update on Treatment Options for Children
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- IL-15 Prolongs Anagen, Stimulates Proliferation, and Suppresses Apoptosis in the Hair Matrix of Human Scalp Hair Follicles
- Hair Loss in Lichen Planopilaris and Frontal Fibrosing Alopecia: Not Always Irreversible
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies
- Biologics in the management of childhood atopic dermatitis
- Interleukin-15 is a hair follicle immune privilege guardian
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
- Comparative characteristics of the effectiveness of drugs for the treatment of alopecia areata in childhood
- Effects of biomaterials derived from germinated hemp seeds for stressed hair stem cells and immune cells
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- Effective treatment of alopecia universalis with oral tofacitinib: A case report
- 870 Y27632 promotes proliferation via EGFR signaling in a newly isolated and characterized human primary sebocyte cell line
- The Good and Bad News About New Drugs for Treating Alopecia Areata